Recently, a batch of Apelise drugs worth approximately 160000 RMB, introduced under the "Hong Kong Macao Pharmaceutical Equipment Connect" policy, were declared to customs and completed customs clearance procedures within 20 minutes. They left Guangzhou Baiyun Airport Comprehensive Bonded Zone and were sent to Shenzhen Qianhai Shekou Free Trade Zone Hospital.

The policy of "Hong Kong and Macao drug and equipment connection" was jointly launched by eight departments, including the State Food and Drug Administration and the General Administration of Customs, in November 2020. It aims to thoroughly implement the Outline of the Development Plan of the Guangdong Hong Kong and Macao Greater Bay Area, and through innovative drug and medical device supervision methods, allow drugs that are urgently needed clinically and have been listed in Hong Kong and Macao, as well as medical devices that are urgently needed clinically and have been purchased and used by public hospitals in Hong Kong and Macao and have progressiveness clinical applications, Used by eligible medical institutions in the mainland of the Guangdong Hong Kong Macao Greater Bay Area. Apelix imported this time belongs to PI3K (intracellular phosphatidylinositol kinase) inhibitor, which is used in combination with fluoxetine to treat advanced or metastatic breast cancer. Through the "Hong Kong Macao Medical Device Connect" policy, international advanced innovative medical devices can quickly enter clinical applications, providing more convenient pharmaceutical and medical device products and services for mainland residents in the Guangdong Hong Kong Macao Greater Bay Area, which is of great significance for promoting the construction of the "Healthy Bay Area".

In response to the policy of "Hong Kong and Macao Drug and Equipment Connect", Guangzhou Customs and Guangdong Provincial Drug Administration have established an information exchange mechanism to actively understand the urgently needed Hong Kong and Macao drugs, medical device varieties, and other information in designated medical institutions. They provide policy guidance throughout the customs clearance process, guide enterprises to do a good job in pre entry packaging, labeling, and accompanying documents review, optimize and simplify the declaration process. At the same time, innovative regulatory models such as "one certificate, multiple batches," "batch by batch, and centralized declaration" for drug clearance in the comprehensive protection zone are being innovated, continuously optimizing the approval process for entering and exiting the zone, and adding reform convenience measures such as two-step declaration and two-stage admission. Intelligent checkpoints are being applied to achieve "7" × 24-hour automatic inspection and release, assisting efficient and smooth customs clearance of drugs and equipment, and serving the integrated development of the biopharmaceutical industry in the Guangdong Hong Kong Macao Greater Bay Area.